Zapping stubborn cancer spots may extend life of current drug therapy

NCT ID NCT06101290

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while receiving stereotactic body radiation or interventional ablation to the progressing tumors. The goal is to see if this combination delays the need to switch or stop systemic therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
What this could lead to: If successful, this approach could help people with certain genitourinary cancers delay changing or stopping their systemic therapy by treating limited tumor growth with targeted local treatment.
What could go wrong: This is a mid-stage trial with 150 participants, so results may not apply to everyone. Local ablative therapy carries risks of side effects like pain, infection, or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOPROGRESSIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer renal cell carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OLIGOPROGRESSIVE PROSTATE CANCER RENAL CELL CARCINOMA UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of California, Davis
RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.